Skip to content

Contact +44 (0) 20 7060 7474 email us

Company Information

Stakeholder Insight Atherosclerosis

HDL, ApoA-I, Carotid MRI and 64-slice CT offer opportunities for future treatment

Publication Date October 2007
Publisher Datamonitor
Product Type Report
Pages 108
ISBN Number not applicable
Product Code DAT00610

Price

£1,980.00
approximately: $2,998 | €2,210

pdf

Buy Now

print £2,010 ($3,043 | €2,243)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction

This analysis examines the historical and forecast performance for Actelion in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information

Reasons to Purchase

  • Benchmark Actelion's performance against key rivals in the ethical pharmaceutical sector
  • Assess Actelion's market leading position in the pulmonary arterial hypertension (PAH) segment
  • Analyze future competition anticipated for Actelion's flagship PAH therapy Tracleer, particularly from Gilead/GSK's ambrisentan

Contents

  • Chapter 1 Executive Summary
    • Key findings
    • Historical and forecast ethical sales performance
    • Therapeutic strategy
    • Launch and expiry outlook
    • Externalization, geographic and molecule type strategies
    • Externalization strategy
    • Geographic strategy
    • Molecule type strategy
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Chapter 2 Corporate History
    • Key findings
    • Background
    • Key corporate developments
    • M&A history
    • Axovan - 2003
    • CoTherix - 2007
    • Current corporate structure
    • Biopharmaceuticals
    • Current management team
  • Chapter 3 Historical Performance
    • Key findings
    • Introduction
    • Revenue and growth rate analysis, 2001-06
    • Revenue and growth rate vs. peer set
    • Product analysis, 2001-06
    • Growth drivers
    • Tracleer
    • Zavesca
    • Operating revenue and cost analysis, 2001-06
    • Operating revenue/cost analysis
  • Chapter 4 Forecast Performance
    • Key findings
    • Introduction
    • Revenue and growth rate, 2006-12
    • Product analysis, 2006-12
    • Growth drivers
    • Tracleer
    • Ventavis
    • Actelion-1
    • Other products
    • Therapy area analysis, 2006-12
    • Cardiovascular & hematology
    • Endocrine, metabolic & genetic disorders and CNS
    • Therapy area focus
    • Launches and expiries analysis, 2006-12
    • Launch portfolio
    • Core portfolio
    • Expiry portfolio
    • Launch/core/expiry configuration
    • Externalization analysis, 2006-12
    • Geographic analysis, 2006-12
    • Molecule type analysis, 2006-12
  • Chapter 5 Key Products And Competitors
    • Key findings
    • Overview
    • Cardiovascular and hematology
    • Tracleer
    • Overview
    • Sales forecast
    • Newsflow
    • Competitive landscape
    • Actelion-1: life cycle management
    • Ventavis
    • Overview
    • Sales forecast
    • Newsflow
    • Competitive landscape
    • Endocrine, metabolic & genetic disorders
    • Zavesca
    • Overview
    • Sales forecast
    • Newsflow
    • Competitive landscape
    • Central nervous system
    • ACT-078573
    • Overview
    • Sales forecast
    • Newsflow
    • Clinical data
    • Patient potential
    • R&D pipeline
  • Chapter 6 Appendix
    • IMS vs. company-reported data reconciliation
    • References
    • Datamonitor reports
    • Abbreviations
    • Exchange rates
  • List of Tables
    • Table 1: Actelion Corporate Executive Committee
    • Table 2: Peer set overview
    • Table 3: Operating revenue/cost analysis ($m), 2001-06
    • Table 4: Operating cost ratio analysis (% of total revenues), 2001-06
    • Table 5: Product portfolio overview, sales ($m), 2006-12
    • Table 6: Therapy area overview, sales ($m), 2006-12
    • Table 7: Launch portfolio overview, sales ($m), 2006-12
    • Table 8: Core portfolio overview, sales ($m), 2006-12
    • Table 9: Externally developed portfolio ($m), 2006-12
    • Table 10: Molecule type overview, sales ($m), 2006-12
    • Table 11: Key products overview
    • Table 12: Tracleer: overview
    • Table 13: Tracleer: sales forecast ($m), 2006-12
    • Table 14: Tracleer: newsflow
    • Table 15: Ventavis: overview
    • Table 16: Ventavis: sales forecast ($m), 2006-12
    • Table 17: Ventavis: news flow
    • Table 18: Zavesca: overview
    • Table 19: Zavesca: sales forecast ($m), 2006-12
    • Table 20: Zavesca: newsflow
    • Table 21: ACT-078573: overview
    • Table 22: ACT-078573: sales forecast ($m), 2006-12
    • Table 23: ACT-078573: newsflow
    • Table 24: Actelion's R&D pipeline (Phase I-registration)
    • Table 25: Exchange rates, 2007
  • List of Figures
    • Figure 1: Historical and forecast ethical sales performance (% CAGR), Actelion and biotechnology peer set
    • Figure 2: Therapeutic focus vs. biotechnology peer set (%), 2006
    • Figure 3: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Actelion
    • Figure 4: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set
    • Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2006
    • Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2012
    • Figure 7: SWOT analysis of Actelion
    • Figure 8: Actelion timeline
    • Figure 9: M&A/divestment history
    • Figure 10: Current corporate structure
    • Figure 11: Revenue & growth rate (ethical sales) ($m), 2001-06
    • Figure 12: Ethical revenue ($m) and growth rate (%) vs. peer set, 2001-06
    • Figure 13: Growth drivers/resistor products of historical revenue performance ($m), 2001-06
    • Figure 14: Operating revenue/cost analysis ($m), 2001-06
    • Figure 15: Operating cost ratio analysis (% of total revenues), 2001-06
    • Figure 16: Ethical revenue ($m) and growth rate (%), 2006-12
    • Figure 17: Top two products by sales ($m), 2006
    • Figure 18: Top five products by sales ($m), 2012
    • Figure 19: Growth drivers and resistors by product, 2006-12
    • Figure 20: Key strategic products, sales ($m), 2006-12
    • Figure 21: Ethical sales by therapy area ($m), 2006-12
    • Figure 22: Growth drivers and resistors by therapy area (%), 2006-12
    • Figure 23: Ethical sales by therapy area (%), 2006-12
    • Figure 24: Therapy area focus compared with peer set (% total ethical sales), 2006
    • Figure 25: Therapy area focus compared with peer set (% total ethical sales), 2012
    • Figure 26: Launch schedule, sales ($m), 2006-12
    • Figure 27: Core products sales growth ($m), 2006-12
    • Figure 28: Launch, core and expiry, sales ($m), 2006-12
    • Figure 29: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Actelion
    • Figure 30: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set
    • Figure 31: Externalization dependency, sales ($m), 2006-12
    • Figure 32: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2006-12
    • Figure 33: Externalization dependency vs. peer set, % total sales, 2006
    • Figure 34: Externalization dependency vs. peer set, % total sales, 2012
    • Figure 35: Geographical sales breakdown ($m), 2006-12
    • Figure 36: Growth drivers and resistors by geography, sales ($m), 2006-12
    • Figure 37: US dependency vs. peer set, % total sales, 2006
    • Figure 38: US dependency vs. peer set, % total sales, 2012
    • Figure 39: Molecule type sales breakdown ($m), 2006-12
    • Figure 40: Growth drivers and resistors by molecule type, sales ($m), 2006-12
    • Figure 41: Biologics dependency vs. peer set, % total sales, 2006
    • Figure 42: Biologics dependency vs. peer set, % total sales, 2012